Continuous glucose monitoring (CGM) has fundamentally changed diabetes management by giving patients and clinicians access to real-time glucose data. As a result, treatment decisions have become more precise, and many people with diabetes now spend more time within their target glucose range. However, glucose represents only one part of the …
Read More »Could Your Smartwatch Detect Diabetes Before a Blood Test?
For decades, diagnosing diabetes has depended on blood tests performed during routine medical visits. However, what if your smartwatch could recognize early warning signs before glucose levels become high enough for a formal diagnosis? Researchers are now exploring wearable technologies for diabetes screening that continuously analyze physiologic data collected throughout …
Read More »Should Patients Still Be Using Flash CGM? Navigating the Shift to Real-Time Monitoring
As diabetes technology continues to evolve, clinicians are increasingly faced with an important question: should patients still be using flash continuous glucose monitoring (CGM), or is it time to switch to real-time CGM? While flash CGM systems have significantly improved glucose monitoring and patient engagement over traditional fingerstick testing, real-time …
Read More »Should Hospitalized Patients Keep Their CGMs and Insulin Pumps? The 2026 Standards Say Yes
For years, hospital admission often meant disconnecting patients from their personal diabetes devices. Continuous glucose monitors (CGMs) and insulin pumps were frequently removed, even when patients had used them successfully at home. However, the 2026 American Diabetes Association (ADA) Standards of Care introduce a significant shift in how hospitals approach …
Read More »Fasting or Random Glucose Testing? Navigating the New Rules for Cancer Therapy–Induced Hyperglycemia
As cancer treatment becomes increasingly sophisticated, clinicians are encountering a growing metabolic challenge. Cancer therapy–induced hyperglycemia has emerged as an important concern with the expanding use of immunotherapies and targeted therapies. In some patients, hyperglycemia develops gradually. In others, particularly those receiving immune checkpoint inhibitors, severe diabetes and diabetic ketoacidosis …
Read More »Why Some Patients Abandon CGM Within Days—and What to Teach Before They Leave the Office
Continuous glucose monitoring (CGM) has transformed diabetes management by giving patients real-time glucose data, trend arrows, and alerts that support better daily decisions. Yet some patients stop using their CGM within days of starting. Often, the problem is not the device itself. Instead, early frustration begins when patients leave the …
Read More »The Overnight Danger Many Clinicians Miss: Why Nighttime Hypoglycemia Still Matters
Many healthcare providers focus heavily on daytime glucose control, yet some of the most dangerous hypoglycemic episodes occur while patients are asleep. Despite major advances in insulin therapy and glucose monitoring, nocturnal hypoglycemia remains a significant clinical concern for people living with diabetes. Because symptoms often go unnoticed during sleep, …
Read More »Why More Hospitals Are Screening Surgical Patients for Undiagnosed Diabetes
Many hospitals now treat surgery as more than a single procedure. Increasingly, it has become an opportunity to uncover hidden health conditions that may otherwise go undetected for years. One important trend is perioperative diabetes screening, which helps health systems identify patients with undiagnosed diabetes and prediabetes before surgery begins. …
Read More »Is Carb Counting Becoming Obsolete? The Rise of Precision Nutrition in Diabetes Care
A bowl of oatmeal can keep one person’s glucose stable while sending another person’s blood sugar sharply upward. The meal is identical, yet the metabolic response is completely different. That reality is pushing many clinicians to reconsider one of the most established principles in diabetes nutrition: carb counting. The growing …
Read More »Cancer Therapy Is Changing Diabetes Management: What Clinicians Need to Know Now
Cancer treatment is evolving rapidly, and with that progress comes a new challenge for clinicians managing glucose disorders. As immune checkpoint inhibitors (ICIs) and PI3K inhibitors become more widely used in oncology, therapy-related hyperglycemia is appearing more often in clinical practice. Many patients receiving cancer treatment now face unexpected glucose …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.